$108M raised by Mainstay Medical to support US launch of back pain implant

Alan Condon -   Print  |

Mainstay Medical raised $108 million to fund the launch of its ReActiv8 implant in the U.S. and pursue post-market clinical studies.

"We are now strongly capitalized to execute on our corporate objectives in 2021 and beyond, including the launch of ReActiv8 in the U.S. market and acceleration of our commercialization efforts in Europe and Australia," Jason Hannon, CEO of Mainstay Medical, said in a Feb. 16 news release.

ReActiv8 is a restorative neurostimulation implant used to treat chronic lumbar pain. The implant stimulates nerves that supply the lumbar multifidus muscle to generate contraction of the muscle, which can help patients recover from chronic lumbar pain.

The funding was raised through an equity financing round that included venture capital firms Sofinnova Partners, Ally Bridge Group and Fountain Healthcare Partners as well as family investment firm KCK Group.

More articles on devices:
Massachusetts, Rhode Island practices to forge 60-plus physician group
3 spine surgeons debut high-speed drills with Mazor robot
Former Medtronic exec to lead Zimmer Biomet's spine spinoff

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers